Eyding D, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and SSRI. BMJ 2010;341:c4737
Reboxetine is no more effective than placebo for major depressive disorder.
Jan
19
Reboxetine for acute treatment of major depression
Tags: BMJ, major depression, reboxetine, SSRI
Log In
Sign up for our mailing list!
Categories
Recent Posts
Recent Comments
- Michael Tam on Cranberry juice fails for urinary tract infections
- Michael Tam on Inhaled corticosteroids as rescue treatment
- Joel Rhee on Inhaled corticosteroids as rescue treatment
- Michael Tam on Incidence and progression of thyroid dysfunction in elderly
- Joel Rhee on Incidence and progression of thyroid dysfunction in elderly
Archives
Tags
antibiotics
antipsychotics
atrial fibrillation
bisphosphonates
BMD
BMJ
cancer
cerebrovascular accident
chronic fatigue syndrome
chronic kidney disease
CID
coronary heart disease
depression
DHA
diabetes
DXA
eGFR
EPA
gliclazide
hypertension
hypoglycaemia
hypothyroidism
incidence
Internal Medicine Journal
JAMA
Lancet
major depression
MJA
MLV
NEJM
older men
omega-3
osteoporosis
pharmaceutical company
PLoS
PNAS
quetiapine
reboxetine
SSRI
statins
subclinical hypothyroidism
thyroxine
UTI
VTE
warfarin
Donate!
We do not accept drug company sponsorship or web based advertising for funding. The operational costs of the website is funded directly by the administrator. Please donate generously to the running costs.